Dr. Tripathy on the Development of Palbociclib in Breast Cancer

Article

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
breast cancer

Biosimilars Make Routine Prophylaxis With G-CSF Feasible in HER2+ Breast Cancer

December 1st 2023
Article

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

November 16th 2023
Article

The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

breast cancer

PFS Significantly Improves With Dato-DXd in HR+, HER2- Metastatic Breast Cancer

October 25th 2023
Article

Patients with metastatic hormone receptor-positive breast cancer treated with datopotamab deruxtecan experienced a statistically significant and clinically meaningful improvement in progression-free survival.

young patient with cancer

Psychological Concerns in the Aftermath of a Breast Cancer Diagnosis and Treatment for Young Adults

October 23rd 2023
Article

Receiving a breast cancer diagnosis and undergoing treatment as a young adult takes a physical and emotional toll.

© 2023 MJH Life Sciences

All rights reserved.